Quadrant Healthcare

Article Abstract:

Quadrant Healthcare should benefit from the settlement of a dispute relating to ownership of a patent, and the dismissal of the founder, Bruce Roser, as chief operating officer. The company will then be able to sign licensing agreements with big drugs companies which have shown interest in Quadrant's core technology. The company could lose its court case but this would only involve losing one patent and paying 3 million pound sterling in damages to Roser.

Drug Delivery Systems, Health care industry, Quadrant Healthcare

---

On track to sustained growth

Article Abstract:

Bangladesh's Square Pharmaceuticals built its reputatiproviding access to advanced technological manufacturing. The firm's market share grew 11% between 1982 and 1996, from 4% to 15%, and offers more than 70 products. A new plant that would double current production capacity is scheduled for construction in 1998.

Pharmaceutical Preparations, Pharmaceutical industry, Drugs, Company Profile, Square Pharmaceuticals

---

Similar abstracts:

• Abstracts: Thumbs up for Glaxo. Phytopharm: Chinese checkers
• Abstracts: Speculating on biotechs. Quadrant Healthcare: Still attractive. The last privatisation
• Abstracts: Picking the best of the promise keepers. Pooling resources to beat the market
• Abstracts: Heart stopping. Shield's big deal. Sum of the parts worth more than the whole
• Abstracts: The operation and interaction of the child tax credit with other personal credits. Individual income tax planning with a FLP/LLC

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.